Información del artículo
El Texto completo está disponible en PDF
Bibliografía
[1.]
T.R. Pedersen, L. Wilhelmsen, O. Faergeman, T.E. Strandberg, G. Thorgeirsson, L. Troedsson, et al.
Follow-up study of patients randomized in Scandinavian Simvastatin Survival Study (4S) of cholesterol lowering.
Am J Cardiol, 86 (2000), pp. 257-262
[2.]
Scandinavian Simvastatin Survival Study Group. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S).
Lancet, 344 (1994), pp. 1383-1389
[3.]
F.M. Sacks, M.A. Pfeffer, L.A. Moye, J.L. Rouleau, J.D. Rutherford, T.G. Cole, et al.
for the Cholesterol and Recurrent Events Trial Investigators. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol level.
N Engl J Med, 335 (1996), pp. 1001-1009
[4.]
The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels.
N. Engl J Med, 339 (1998), pp. 1349-1357
[5.]
B. Pitt, D. Waters, W.V. Brown, A.J. Van Boven, L. Schwartz, L.M. Title, et al.
and the Atorvastatin Versus Revascularization Treatment Investigators. Agressive lipid-lowering therapy compared with angioplasty in stable coronary artery disease.
N Engl J Med, 341 (1999), pp. 70-76
[6.]
J. Shepherd, S.M. Cobbe, I. Ford, C.G. Isless, A.R. Lorimer, P.W. Macfarlane, et al.
for the West of Scotland Coronary Prevention Study group. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia.
N Engl J Med, 333 (1995), pp. 1301-1307
[7.]
J.R. Downs, M. Clearfield, S. Weis, E. Whitney, D.R. Shapiro, P.A. Beere, et al.
for the AFCAPS/TexCAPS Research Group. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS.
JAMA, 279 (1998), pp. 1515-1622
[8.]
J.J.P. Kastelein.
The future of best practice.
Atherosclerosis, 143 (1999), pp. 17-21
[9.]
T.A. Jacobson, J.R. Schein, A. Williamson, C.M. Ballantyne.
Maximizing the cost-effectiveness of lipid-lowering therapy.
Arche Intern Med, 158 (1998), pp. 1977-1989
[10.]
Report of the Program on the Surgical Control of the Hyperlipidemias (POSCH). Effect of partial ileal bypass surgery on mortality and morbidity from coronary heart disease in patients with hypercholesterolemia.
N Engl J Med, 323 (1990), pp. 946-955
[11.]
G.F. Watts, B. Lewis, J.N.H. Brunt, E.S. Lewis, D.J. Coltart, L.D.R. Smith, et al.
Effects on coronary artery disease of lipid-lowering diet, or diet plus cholestyramine, in the St Thomas Atherosclerosis Regression Study (STARS.
Lancet, 339 (1992), pp. 563-569
[12.]
G. Brown, J.J. Albers, D. Fisher Ll, S.M. Schaefer, J.T. Lin, C. Kaplan, et al.
Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B.
N Engl J Med, 323 (1990), pp. 1289-1298
[13.]
J.A. Herd, C.M. Ballantyne, J.A. Farmer, J.J. Ferguson, P.H. Jones, S. West, et al.
for the LCAS Investigators. Effects of fluvastatin on coronary atherosclerosis in patients with mild to moderate cholesterol elevations (lipoprotein and coronary atherosclerosis study-LCAS.
Am J Cardiol, 80 (1997), pp. 278-286
[14.]
The Post Coronary Artery Bypass Graft Trial Investigators. The effect of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation on obstructive changes in saphenous-vein coronary-artery bypass grafts.
N Engl J Med, 336 (1997), pp. 153-162
[15.]
D. Waters, L. Higginson, P. Gladstone, B. Kimball, M. Le May, S.J. Boccuzzi, et al.
for the CCAIT Study group. Effect of monotherapy with an HMG-CoA reductase inhibitor on the progression of coronary atherosclerosis as assessed by serial quantitative arteriography. The Canadian Coronary Atherosclerosis Intervention Trial.
Circulation, 89 (1994), pp. 959-968
[16.]
J.W. Jukema, A.V.G. Bruschke, A.J. Van Boven, J.H.C. Reiber, E.T. Bal, A.H. Zwinderman, et al.
and the REGRESS Study Group. Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels. The Regression Growth Evaluation Statin Study (REGRESS.
Circulation, 91 (1995), pp. 2528-2540
Copyright © 2001. Sociedad Española de Arteriosclerosis y Elsevier España, S.L.